Current Opinion in Virology, Journal Year: 2021, Volume and Issue: 52, P. 9 - 14
Published: Nov. 9, 2021
Language: Английский
Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2021, Volume and Issue: 15(4), P. 102146 - 102146
Published: May 21, 2021
Language: Английский
Citations
1012
The Lancet Microbe, Journal Year: 2023, Volume and Issue: 4(3), P. e179 - e191
Published: Feb. 1, 2023
BackgroundFrequent use of antibiotics in patients with COVID-19 threatens to exacerbate antimicrobial resistance. We aimed establish the prevalence and predictors bacterial infections resistance COVID-19.MethodsWe did a systematic review meta-analysis studies co-infections (identified within ≤48 h presentation) secondary (>48 after outpatients or hospitalised COVID-19. searched WHO Research Database identify cohort studies, case series, case-control trials, randomised controlled trials populations at least 50 published any language between Jan 1, 2019, Dec 2021. Reviews, editorials, letters, pre-prints, conference proceedings were excluded, as which infection was not microbiologically confirmed (or via nasopharyngeal swab only). screened titles abstracts papers identified by our search, then assessed full text potentially relevant articles. reported pooled doing random-effects meta-regression. Our primary outcomes co-infection infection, antibiotic-resistant pathogens among laboratory-confirmed infections. The study protocol registered PROSPERO (CRD42021297344).FindingsWe included 148 362 976 patients, done December, May, 5·3% (95% CI 3·8–7·4), whereas 18·4% (14·0–23·7). 42 (28%) comprehensive data for Among people infections, proportion that resistant antimicrobials 60·8% 38·6–79·3), isolates 37·5% (26·9–49·5). Heterogeneity organisms substantial (I2=95%).InterpretationAlthough infrequently assessed, is highly prevalent Future research surveillance assessing effect on patient population level are urgently needed.FundingWHO.
Language: Английский
Citations
108
Journal of Fungi, Journal Year: 2021, Volume and Issue: 7(9), P. 720 - 720
Published: Sept. 2, 2021
Patients with severe COVID-19, such as individuals in intensive care units (ICU), are exceptionally susceptible to bacterial and fungal infections. The most prevalent infections aspergillosis candidemia. Nonetheless, other species (for instance,
Language: Английский
Citations
83
Open Forum Infectious Diseases, Journal Year: 2021, Volume and Issue: 8(12)
Published: Sept. 7, 2021
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has overwhelmed healthcare facilities and raises an important novel concern nosocomial transmission Candida species in the intensive care units (ICUs).We evaluated incidence risk factors for development candidemia 2384 COVID-19 patients admitted during August 2020-January 2021 ICUs 2 hospitals (Delhi Jaipur) India. A 1:2 case-control matching was used to identify who did not develop as controls.A total 33 developed accounted overall 1.4% over a median ICU stay 24 days. 2-fold increase versus non-COVID-19 observed with rate 14 15/1000 admissions ICUs. auris predominant (42%) followed by tropicalis. Multivariable regression analysis revealed use tocilizumab, duration (24 vs days), raised ferritin level independent predictor candidemia. Azole resistance C tropicalis harboring mutations azole target ERG11 gene. Multilocus sequence typing (MLST) identified identical genotypes patients, raising resistant strains.Secondary bacterial infections have been tocilizumab. In this cohort critically ill tocilizumab associated Surveillance antifungal is warranted prevent multidrug-resistant strains yeasts hospitalized patients.
Language: Английский
Citations
71
Beni-Suef University Journal of Basic and Applied Sciences, Journal Year: 2022, Volume and Issue: 11(1)
Published: March 7, 2022
The novel coronavirus has embarked on a global pandemic and severe mortality with limited access for its treatments medications. For the lack of time, research, enough efficacy, most vaccines are underdeveloped or unreachable to society. However, many recent studies suggest various alternative, complementary remedies COVID-19, which functional foods. This review provides an overview how foods can play great role through modulating host immune system, generating antiviral activities, synthesizing biologically active agents effective against coronavirus.
Language: Английский
Citations
42
Journal of Infection and Public Health, Journal Year: 2022, Volume and Issue: 15(4), P. 466 - 479
Published: Feb. 18, 2022
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is yet to be controlled worldwide, especially in India. second wave of disease 2019 (COVID-19) led panic and confusion India, owing the overwhelming number population that fell prey this highly infectious virus recent times. In COVID-19, patients had fight both opportunistic infections triggered fungi bacteria. Repeated use steroids, antibiotics, oxygen masks during management severely critically ill COVID-19 nurtured such as mucormycosis. Despite mucormycosis being a decades-old disease, it has gained notice its widespread occurrence throughout Instances are usually unearthed immunocompromised individuals inhalation filamentous fungi, either from natural environment or through supportive care units. outbreak been seen cause secondary infection grows along with treatment COVID-19. Furthermore, comorbidities diabetes were more likely have co-infection because their challenged immune systems' inability it. hype, still remains neglected least studied, which predominantly due all focus on diagnostics, vaccine, therapeutic research. review, we emphasize mainly association patients. We also present molecular mechanism for better understanding fungal who recently infected SARS-CoV-2. Better pathogens, immediate diagnosis, crucial patients, high mortalities recorded co-infected despite recovery
Language: Английский
Citations
40
Medical Journal Armed Forces India, Journal Year: 2021, Volume and Issue: 77, P. S289 - S295
Published: July 1, 2021
Language: Английский
Citations
53
JAC-Antimicrobial Resistance, Journal Year: 2022, Volume and Issue: 5(1)
Published: Dec. 7, 2022
Coronavirus disease 2019 (COVID-19) changed healthcare across the world. With this change came an increase in healthcare-associated infections (HAIs) and a concerning concurrent proliferation of MDR organisms (MDROs). In narrative review, we describe impact COVID-19 on HAIs MDROs, potential causes these changes, discuss future directions to combat observed rise rates MDRO infections.
Language: Английский
Citations
36
Cureus, Journal Year: 2022, Volume and Issue: unknown
Published: March 31, 2022
The prevalence, incidence, and characteristics of bacterial infections in patients infected with severe acute respiratory syndrome coronavirus 2 are not well understood have been raised as an important knowledge gap. Therefore, our study focused on the most common opportunistic infections/secondary infections/superinfections disease 2019 (COVID-19) patients. This systematic review meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews Meta-Analyses. Eligible studies were identified using PubMed/Medline since inception June 25, 2021. Studies meeting inclusion criteria selected. Statistical analysis Review Manager 5.4.1. A random-effect model used when heterogeneity seen pool studies, result reported inverse variance corresponding 95% confidence interval. We screened 701 articles comprising 22 cohort which included analysis. pooled prevalence 16% COVID-19 highest secondary observed among viruses at 33%, followed by bacteria 16%, fungi 6%, 25% miscellaneous group/wrong outcome. Opportunistic more prevalent critically ill isolated pathogens Epstein-Barr virus, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Hemophilus influenza, invasive pulmonary aspergillosis. Large-scale required better identify opportunistic/secondary/superinfections
Language: Английский
Citations
32
Microbiology Spectrum, Journal Year: 2021, Volume and Issue: 9(2)
Published: Oct. 20, 2021
The aim of this study was to evaluate diagnostic means, host factors, delay occurrence, and outcome patients with COVID-19 pneumonia fungal coinfections in the intensive care unit (ICU). From 1 February 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), pneumocystosis (CA-PCP) from 36 centers, including results on biomarkers respiratory specimens serum. We collected data 154 episodes CAPA, 81 CA-fungemia, 17 CA-PCP, 5 other mold infections 244 (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, day; interquartile range [IQR], 0 3 days), followed by CAPA (9 days; IQR, 13 then CA-fungemia (16 12 23 days) (P < 10-4). For presence several mycological criteria associated death Serum galactomannan rarely positive (<20%). mortality rates were 76.7% (23/30) factors for invasive disease, 45.2% (14/31) those a preexisting condition, 36.6% (34/93) remaining 0.001). Antimold treatment did not alter prognosis 0.370). Candida albicans responsible 59.3% CA-fungemias, global 45.7%. 58.8% known PCP, rate 29.5%. may be part hospital acquired could benefit antifungal prescription at biomarker result. appeared linked stay without specificity, while really concern ICU. Improved strategy markers should support these hypotheses. IMPORTANCE To diagnose unit, it is necessary implement correct prevent them if possible. remain best approach since serum are positive. Timing occurrence suggests that acquired. varies when no or diseases present, respectively. Fungemias 2 weeks ICUs yeast species recovered, specificity COVID-19. Pneumocystosis mainly found immunodepression. diagnosis entry afterwards, suggesting Pneumocystis jirovecii plays role, upstream hospitalization
Language: Английский
Citations
40